1.285 USD
-0.03 (-1.91%)
CPHI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. CPHI has a bad profitability rating. Also its financial health evaluation is rather negative. CPHI has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
CPHI had negative earnings in the past year.
CPHI had a positive operating cash flow in the past year.
CPHI had negative earnings in each of the past 5 years.
In the past 5 years CPHI always reported negative operating cash flow.
1.2 Ratios
CPHI's Return On Assets of -26.56% is in line compared to the rest of the industry. CPHI outperforms 55.73% of its industry peers.
CPHI has a Return On Equity of -56.58%. This is comparable to the rest of the industry: CPHI outperforms 49.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.56% | ||
| ROE | -56.58% | ||
| ROIC | N/A |
ROA(3y)-24.28%
ROA(5y)-20.29%
ROE(3y)-65.01%
ROE(5y)-57.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CPHI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CPHI has been increased compared to 1 year ago.
CPHI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CPHI has a worse debt to assets ratio.
2.2 Solvency
CPHI has an Altman-Z score of -4.86. This is a bad value and indicates that CPHI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.86, CPHI is doing worse than 63.02% of the companies in the same industry.
The Debt to FCF ratio of CPHI is 48.73, which is on the high side as it means it would take CPHI, 48.73 years of fcf income to pay off all of its debts.
CPHI has a better Debt to FCF ratio (48.73) than 73.96% of its industry peers.
CPHI has a Debt/Equity ratio of 0.53. This is a neutral value indicating CPHI is somewhat dependend on debt financing.
CPHI has a Debt to Equity ratio of 0.53. This is in the lower half of the industry: CPHI underperforms 64.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 48.73 | ||
| Altman-Z | -4.86 |
ROIC/WACCN/A
WACC7.42%
2.3 Liquidity
A Current Ratio of 0.51 indicates that CPHI may have some problems paying its short term obligations.
With a Current ratio value of 0.51, CPHI is not doing good in the industry: 91.67% of the companies in the same industry are doing better.
A Quick Ratio of 0.19 indicates that CPHI may have some problems paying its short term obligations.
CPHI has a worse Quick ratio (0.19) than 92.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.51 | ||
| Quick Ratio | 0.19 |
3. Growth
3.1 Past
CPHI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.70%, which is quite impressive.
Looking at the last year, CPHI shows a very negative growth in Revenue. The Revenue has decreased by -29.64% in the last year.
CPHI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -16.15% yearly.
EPS 1Y (TTM)74.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.84%
Revenue 1Y (TTM)-29.64%
Revenue growth 3Y-22.27%
Revenue growth 5Y-16.15%
Sales Q2Q%10.91%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CPHI. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
76.04% of the companies in the same industry are more expensive than CPHI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 91.76 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CPHI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSEARCA:CPHI (12/26/2025, 4:15:00 PM)
1.285
-0.03 (-1.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.52%
Inst Owner Change-52.77%
Ins Owners53.39%
Ins Owner Change0%
Market Cap6.45M
Revenue(TTM)4.40M
Net Income(TTM)-3.66M
Analysts0
Price TargetN/A
Short Float %0.25%
Short Ratio0.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.47 | ||
| P/FCF | 91.76 | ||
| P/OCF | 15.19 | ||
| P/B | 1 | ||
| P/tB | 294.55 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.58
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.01
FCFY1.09%
OCF(TTM)0.08
OCFY6.59%
SpS0.88
BVpS1.29
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.56% | ||
| ROE | -56.58% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 1.6% |
ROA(3y)-24.28%
ROA(5y)-20.29%
ROE(3y)-65.01%
ROE(5y)-57.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 48.73 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 19.75% | ||
| Cap/Sales | 8.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.51 | ||
| Quick Ratio | 0.19 | ||
| Altman-Z | -4.86 |
F-Score5
WACC7.42%
ROIC/WACCN/A
Cap/Depr(3y)8.82%
Cap/Depr(5y)14.6%
Cap/Sales(3y)3.86%
Cap/Sales(5y)4.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.84%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-29.64%
Revenue growth 3Y-22.27%
Revenue growth 5Y-16.15%
Sales Q2Q%10.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y106.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y148.16%
OCF growth 3YN/A
OCF growth 5YN/A
CHINA PHARMA HOLDINGS INC / CPHI FAQ
Can you provide the ChartMill fundamental rating for CHINA PHARMA HOLDINGS INC?
ChartMill assigns a fundamental rating of 1 / 10 to CPHI.
What is the valuation status for CPHI stock?
ChartMill assigns a valuation rating of 1 / 10 to CHINA PHARMA HOLDINGS INC (CPHI). This can be considered as Overvalued.
What is the profitability of CPHI stock?
CHINA PHARMA HOLDINGS INC (CPHI) has a profitability rating of 1 / 10.
How financially healthy is CHINA PHARMA HOLDINGS INC?
The financial health rating of CHINA PHARMA HOLDINGS INC (CPHI) is 1 / 10.